	Application No.	Applicant(s)
Examiner-Initiated Interview Summa	09/719,088	HERZOG, HERBERT
Lammer-initiated interview Summe	Examin r	Art Unit
	J. Eric Angell	1635
All Participants:	Status f Applicatio	n:
(1) <u>J. Eric Angell</u> .	(3)	
(2) <u>Chris Brody</u> .	(4)	
Date of Interview: 16 September 2003	Time:	
Type of Interview: ☐ Telephonic ☐ Video Conference ☐ Personal (Copy given to: ☐ Applicant Exhibit Shown or Demonstrated: ☐ Yes ☐ Yes, provide a brief description:] Applicant's representative) No	
Part I.		•
Rejection(s) discussed: None		
Claims discussed: All pending claims		
Prior art documents discussed: None		
Part II.		•
SUBSTANCE OF INTERVIEW DESCRIBING THE	E GENERAL NATURE OF WHA	T WAS DISCUSSED:
Applicants were asked to allow the attached Examiner's amendment in order to expedite the issuance of the Notice of Allowability. Chris Brody indicated that the Applicants agreed to the attached Exainer's amendment.		
Part III.		
 ☑ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability. ☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above. 		
	·	
(Examiner/SPE Signature) (A	Applicant/Applicant's Representa	tive Signature – if appropriate)

Notice to Comply

Application No.
O9/719,088

Examiner

J. Eric Angell

Applicant(s)
HERZOG
Art Unit
1635

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

\boxtimes	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other: _
	oplicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its try into the specification .
apı	A statement that the content of the paper and computer readable copies are the same and, where plicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.25(d).
Fo	or questions regarding compliance to these requirements, please contact:
Fo	r Rules Interpretation, call (703) 308-4216 or (703) 308-2923 or CRF Submission Help, call (703) 308-4212 otentin Software Program Support